Pentixapharm is a clinical-stage radiopharmaceutical development company founded in 2019 with its offices in Berlin and Würzburg, Germany. It is committed to developing CXCR4 ligand-based first-in-class radiopharmaceutical approaches for diagnostic and therapeutic programs in a number of hematological and solid cancers, as well as cardiovascular, endocrine and inflammatory diseases. The specific binding of the ligand to the pathological surface structure of the target cell is identical for both diagnosis and therapy, enabling a theranostic mode of action.